NCT05479591View on ClinicalTrials.gov

A Research Study Looking at Blood Sugar Control in People With Type 2 Diabetes Previously Treated With Premix Insulin and Initiating Treatment With Insulin Degludec/Liraglutide (IDegLira) in Local Clinical Practice in Croatia

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

July 30, 2022

Primary Completion Date

April 30, 2023

Study Completion Date

April 30, 2023

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

IDegLira

Participants will be treated with IDegLira at the treating physician's discretion according to the approved IDegLira label in Croatia and independent from the decision to include the participant in the study.

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT05479591 - A Research Study Looking at Blood Sugar Control in People With Type 2 Diabetes Previously Treated With Premix Insulin and Initiating Treatment With Insulin Degludec/Liraglutide (IDegLira) in Local Clinical Practice in Croatia | Biotech Hunter | Biotech Hunter